Clinical Trial

Pattern Separation in Major Depressive Disorder

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-25
notable Primary completion moved earlier: 2028-08 -> 2027-06-30 2026-06-25
minor Completion moved earlier: 2028-08 -> 2027-06-30 2026-06-25
Trial Details
NCT Number NCT07139834
Lead Sponsor Jeffrey Miller
Conditions Major Depressive Disorder (MDD)
Enrollment 30 participants
Start Date 2026-06-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-14